Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956633 | 0.84 | TGFBR1 (0.54) | TGFBR1MAPK14LMNAMAPTMAPK1 | |
| SCHEMBL5956381 | 0.83 | TGFBR1 (0.46) | TGFBR1MAPK14KDR | |
| SCHEMBL5956685 | 0.81 | TGFBR1 (0.48) | TGFBR1MAPK14LMNAMAPTMAPK1 | |
| SCHEMBL5956435 | 0.81 | TGFBR1 (0.48) | TGFBR1MAPK14EGFR | |
| SCHEMBL5956379 | 0.79 | TGFBR1 (0.48) | TGFBR1MAPK14LMNAMAPTMAPK1 | |
| SCHEMBL5956378 | 0.79 | TGFBR1 (0.48) | TGFBR1MAPK14LMNAMAPTMAPK1 | |
| SCHEMBL5956506 | 0.79 | TGFBR1 (0.46) | TGFBR1MAPK14LMNAMAPTMAPK1 | |
| SCHEMBL5956473 | 0.78 | TGFBR1 (0.48) | TGFBR1MAPK14LMNAMAPTALDH1A1 | |
| SCHEMBL5956656 | 0.76 | PRKAB2 (0.49) | TGFBR1MAPK14 | |
| SCHEMBL4033864 | 0.75 | TGFBR1 (0.82) | TGFBR1MAPK14LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | claimed |
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
| EP-1554275-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004013134-A2 | COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 297/4885LMNA 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.